Scope and Claims Breakdown for US Patent 9,504,699 (Prednisone Delayed-Release Once-Daily Bedtime Method for Rheumatic Disease After IR Glucocorticoid Failure)
US Patent 9,504,699 is directed to a specific clinical-use method: switching a patient with rheumatic disease from an oral immediate-release (IR) glucocorticoid to prednisone in a delayed-release (DR) oral solid administered daily at or before bedtime for defined durations. The claim set narrows the therapeutic window through (i) disease framing, (ii) a “previous IR treatment” predicate, and (iii) formulation performance features (lag time, dissolution after lag, and pH independence). The independent claim is a method-of-treatment claim anchored to a particular administration schedule and a particular drug-release profile, with dependent claims layering duration, disease types, and drug-release parameters.
What is US Patent 9,504,699’s claim scope and what does it cover?
Executive answer: The patent covers US-method treatment of rheumatic disease patients by administering prednisone in a tablet or capsule delayed-release dosage form once daily at or before bedtime as a step-change from prior oral immediate-release glucocorticoid therapy, for at least about 2 weeks, with optional dependent claim coverage for longer courses and specific release kinetics.
Independent claim 1: core elements (scope-defining “must-haves”)
Claim 1 requires all of the following:
-
Patient population predicate
- “A patient suffering from signs and symptoms of an underlying rheumatic disease”
- who previously been treated with “an oral immediate release dosage form of a glucocorticoid”
-
Active ingredient
- “administering daily, at or before bedtime, for at least about two weeks”
- an “effective amount of prednisone”
-
Dosage form definition
- prednisone is “contained in a delayed-release dosage form”
- delayed-release dosage form is “a tablet or a capsule”
-
Administration timing
- “at or before bedtime” and “daily”
Claim scope implication for enforcement
- A practicing clinician or provider method infringement theory would require evidence that the treated patient previously received an IR oral glucocorticoid, and then received prednisone in a DR tablet/capsule at/around bedtime for the stated minimum duration.
- The timing element (“at or before bedtime”) and the “previous IR glucocorticoid” predicate are narrow but also practical in medical records and prescribing history.
Dependent claims 2–5: duration ladder
These claims progressively expand coverage to longer treatment courses if the same method elements of claim 1 are met:
- Claim 2: at least about 4 weeks
- Claim 3: at least about 8 weeks
- Claim 4: at least about 12 weeks
- Claim 5: at least about 12 months
Scope implication
- A commercial risk assessment should treat durations as a continuum: a generic or alternative DR product that is prescribed for shorter than 2 weeks is outside the claim, while treatment lasting ≥2 weeks starts within claim 1 coverage. Longer-duration prescribing increases overlap with dependent claims.
Dependent claim 6: disease genus
- “rheumatic disease is rheumatoid arthritis, ankylosing spondylitis and/or polymyalgia rheumatica”
Scope implication
- If the “underlying rheumatic disease” is outside these listed diseases, claim 6 would not apply, but claim 1 still covers “underlying rheumatic disease” generally. Claim 6, however, strengthens disease-specific infringement narratives and likely matches labeled/clinical use contexts.
What formulation and release-kinetics limits narrow US 9,504,699?
US 9,504,699 includes three dependent formulation performance limits that materially constrain the DR dosage form definition beyond “delayed release” as a general label concept.
Claim 7: lag time (time-to-start delay)
- Delayed-release dosage form has a lag time “from about 3 hours to about 5 hours after administration.”
Scope implication
- “Lag time” becomes a technical hook. A competitor product with a DR profile that starts release outside ~3–5 hours likely avoids claim 7 even if it is delayed and bedtime-administered prednisone.
Claim 8: dissolution time after reaching lag
- “dissolution time of equal to or less than about 2 hours after the lag time is reached.”
Scope implication
- This is a post-lag release-speed requirement. It can be tested via dissolution methods aligned to the patent’s defined or described testing framework.
Claim 9: pH-independent release behavior
- “drug release behaviour which is independent of pH.”
Scope implication
- This limits formulations that rely on pH-triggered dissolution/erosion. Enteric or pH-dependent polymer systems may fall outside this claim element depending on how “independent” is interpreted in the patent’s specification and how a competitor tests.
How do the claims fit together as a “coverage matrix” for infringement risk?
Practical coverage matrix (claim elements as toggles)
| Requirement |
Claim 1 (baseline) |
Claim 2–5 (duration) |
Claim 6 (disease) |
Claim 7 (lag) |
Claim 8 (dissolution after lag) |
Claim 9 (pH independence) |
| Prednisone (DR) in tablet/capsule |
Yes |
Yes |
Yes |
Conditional |
Conditional |
Conditional |
| Administer daily at/before bedtime |
Yes |
Yes |
Yes |
Conditional |
Conditional |
Conditional |
| ≥2 weeks minimum |
Yes |
Yes |
Yes |
Conditional |
Conditional |
Conditional |
| Prior IR oral glucocorticoid treatment |
Yes |
Yes |
Yes |
Conditional |
Conditional |
Conditional |
| Disease = RA/AS/PMR |
Not required |
Not required |
Optional |
Conditional |
Conditional |
Conditional |
| Lag time 3–5 hours |
Not required |
Not required |
Not required |
Yes |
Conditional |
Conditional |
| Dissolution ≤2 hours after lag reached |
Not required |
Not required |
Not required |
Not required |
Yes |
Conditional |
| pH-independent release |
Not required |
Not required |
Not required |
Not required |
Not required |
Yes |
What this means for “design-around”
- If a competitor keeps bedtime dosing + prednisone DR + prior IR predicate but changes release profile outside the lag/dissolution/pH constraints, it may avoid dependent claim coverage (7–9) while still potentially risking independent claim 1 depending on how the specification defines “delayed-release dosage form.”
- If a competitor changes the administration schedule (not “at or before bedtime”) or removes the “prednisone after prior IR glucocorticoid” predicate, it may reduce risk across all claims, but those changes may conflict with therapeutic intent and real-world prescribing patterns.
What patent landscape surrounds US 9,504,699 in the US?
A complete landscape requires the patent’s publication number, assignee, and the family members (continuations/divisionals, related DR prednisone filings, and any formulation process patents). Those details are not provided in the prompt. Without the patent’s bibliographic and family data, the analysis cannot reliably enumerate:
- related continuations or divisionals,
- related formulation/process patents,
- method-of-use patents in the same family,
- any Orange Book listings or FDA-referenced drug products,
- Paragraph IV litigation history tied to the specific DR prednisone product.
Because the requested deliverable is “detailed analysis” of scope and landscape, and because the claim text alone is insufficient to map ownership, priority dates, and family breadth, no landscape tables can be produced without risking factual errors.
How strong is the enforceability of US 9,504,699 based on claim structure?
Enforceability profile based on the claim architecture:
-
Method-of-treatment claims
- Infringement ties to clinical practice and prescribing records.
- Proof depends on documenting “previous IR glucocorticoid treatment” plus bedtime/daily dosing and duration.
-
Strong narrowing through clinical predicate and scheduling
- The “previously treated with oral immediate release glucocorticoid” predicate is a meaningful limiter.
- Bedtime timing (“at or before bedtime”) is a further narrow element.
-
Formulation-specific dependent claims (7–9) provide technical fencing
- Lag time 3–5 hours
- dissolution ≤2 hours after lag
- pH-independent release
These can be attacked by showing the competitor’s product has different release characteristics under relevant testing methods.
-
Duration ladder supports long-course prescribing
- Dependent claims 2–5 create multiple infringement “hooks” across prescribing durations.
- A product competing for shorter courses may still face claim 1 exposure if treatment lasts ≥2 weeks.
Net effect: The patent is likely strongest where the competitive product is a prednisone DR tablet/capsule intended for bedtime dosing with a release profile matching the lag/dissolution/pH constraints, and where patient switching from IR glucocorticoids is part of the standard care path.
What would a generic or alternative DR product need to avoid to reduce risk?
Based on the claim text, risk reduction strategies are tied to claim elements:
Avoid the prior-IR switch predicate
- If the method is not practiced against a patient who “previously been treated” with an oral IR glucocorticoid, claim 1’s predicate may not be met.
Avoid bedtime timing
- If dosing is not “at or before bedtime” (or is administered at different times such that the method is not practiced), claim 1 is weakened.
Avoid the DR profile fence (claims 7–9)
- Lag time outside ~3–5 hours
- Dissolution after lag exceeding ~2 hours
- pH-dependent release behavior
Note: Avoiding claims 7–9 does not necessarily avoid claim 1 unless “delayed-release dosage form” is interpreted in the specification to require those performance parameters. But the dependent claims create explicit technical boundaries that courts often treat as meaningful.
What does claim scope suggest about the likely intended product concept?
The claim set signals a product designed to:
- take advantage of circadian timing by dosing at/around bedtime,
- delay onset of prednisone release by several hours (lag 3–5 hours),
- then release within a short window (dissolution within ≤2 hours after lag),
- use a polymer system with pH-independent release behavior.
That combination is consistent with a specific DR technology rather than generic “delayed release” broadly.
Key Takeaways
- US 9,504,699 claim 1 covers a bedtime, once-daily switch strategy: prednisone in a delayed-release tablet or capsule for ≥2 weeks in patients with rheumatic disease who previously received an oral immediate-release glucocorticoid.
- Dependent claims 2–5 expand coverage to ≥4 weeks, ≥8 weeks, ≥12 weeks, and ≥12 months.
- Claim 6 narrows disease to rheumatoid arthritis, ankylosing spondylitis, and/or polymyalgia rheumatica (while claim 1 remains broader).
- Dependent claims 7–9 provide technical constraints on the DR formulation:
- lag time 3–5 hours
- ≤2 hours dissolution after lag
- pH-independent release behavior
- The strongest infringement narratives are tied to (i) documented prior IR glucocorticoid treatment, (ii) bedtime administration and dosing duration, and (iii) DR release kinetics consistent with the lag/dissolution/pH constraints.
FAQs
-
How does “previously been treated” with an oral immediate-release glucocorticoid affect infringement proof for US 9,504,699?
It makes prescribing and medical history central to establishing the method steps in claim 1.
-
If a competitor’s prednisone delayed-release product has a lag time outside 3–5 hours, can it still infringe claim 1?
Claim 7 would be avoided, but claim 1 could still be implicated if the product is still “delayed-release” as construed under the patent.
-
Does US 9,504,699 require prednisone administration for exactly 2 weeks or just at least about 2 weeks?
The claim requires “at least about two weeks,” so longer durations can satisfy the baseline.
-
What is the practical difference between claim 2 (≥4 weeks) and claim 1 (≥2 weeks) for litigation strategy?
Claim 2 provides an additional, higher-duration hook that aligns with longer-course prescribing.
-
How do the pH-independence limitations in claim 9 guide formulation design-around approaches?
They steer away from pH-triggered release systems toward release behavior that is not materially dependent on pH across relevant GI conditions.
References
No sources were provided or cited beyond the claim text included in the prompt.
